The New England journal of medicine
-
Randomized Controlled Trial Multicenter Study
Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy.
B-cell anomalies play a role in the pathogenesis of membranous nephropathy. B-cell depletion with rituximab may therefore be noninferior to treatment with cyclosporine for inducing and maintaining a complete or partial remission of proteinuria in patients with this condition. ⋯ Rituximab was noninferior to cyclosporine in inducing complete or partial remission of proteinuria at 12 months and was superior in maintaining proteinuria remission up to 24 months. (Funded by Genentech and the Fulk Family Foundation; MENTOR ClinicalTrials.gov number, NCT01180036.).
-
Historical Article
Phage Display to Detect and Identify Autoantibodies in Disease.